NZ594055A - New stable formulations of recombinant human albumin-human granulocyte colony stimulating factor fusion protein - Google Patents

New stable formulations of recombinant human albumin-human granulocyte colony stimulating factor fusion protein

Info

Publication number
NZ594055A
NZ594055A NZ594055A NZ59405510A NZ594055A NZ 594055 A NZ594055 A NZ 594055A NZ 594055 A NZ594055 A NZ 594055A NZ 59405510 A NZ59405510 A NZ 59405510A NZ 594055 A NZ594055 A NZ 594055A
Authority
NZ
New Zealand
Prior art keywords
stimulating factor
colony stimulating
granulocyte colony
recombinant human
fusion protein
Prior art date
Application number
NZ594055A
Other languages
English (en)
Inventor
Jason Benjamin Bock
Xia Luo
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of NZ594055A publication Critical patent/NZ594055A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A61K38/385—Serum albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NZ594055A 2009-01-16 2010-01-15 New stable formulations of recombinant human albumin-human granulocyte colony stimulating factor fusion protein NZ594055A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14544009P 2009-01-16 2009-01-16
US14543609P 2009-01-16 2009-01-16
PCT/US2010/021235 WO2010083434A2 (en) 2009-01-16 2010-01-15 New stable formulations of recombinant human albumin-human granulocyte colony stimulating factor

Publications (1)

Publication Number Publication Date
NZ594055A true NZ594055A (en) 2013-03-28

Family

ID=42260335

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ594055A NZ594055A (en) 2009-01-16 2010-01-15 New stable formulations of recombinant human albumin-human granulocyte colony stimulating factor fusion protein
NZ594056A NZ594056A (en) 2009-01-16 2010-01-15 New stable formulations of recombinant human albumin-human granulocyte colony stimulating factor fusion protein

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ594056A NZ594056A (en) 2009-01-16 2010-01-15 New stable formulations of recombinant human albumin-human granulocyte colony stimulating factor fusion protein

Country Status (16)

Country Link
US (4) US20100227818A1 (enExample)
EP (2) EP2387420A2 (enExample)
JP (2) JP2012515222A (enExample)
KR (2) KR20110132326A (enExample)
CN (2) CN102395379B (enExample)
AU (2) AU2010204547B2 (enExample)
BR (2) BRPI1005159A2 (enExample)
CA (2) CA2749802C (enExample)
EA (2) EA023344B1 (enExample)
IL (2) IL214051A0 (enExample)
MX (2) MX2011007583A (enExample)
NZ (2) NZ594055A (enExample)
SG (3) SG172941A1 (enExample)
UA (2) UA103221C2 (enExample)
WO (2) WO2010083434A2 (enExample)
ZA (1) ZA201105171B (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2387420A2 (en) * 2009-01-16 2011-11-23 Teva Pharmaceutical Industries Limited New stable formulations of recombinant human albumin-human granulocyte colony stimulating factor fusion protein
EP2384759A1 (en) 2010-05-06 2011-11-09 Suomen Punainen Risti Veripalvelu Sulphated hyaluronic acid in combination with G-CSF for use in mobilising blood stem cells
JP5981423B2 (ja) * 2010-06-07 2016-08-31 アムジエン・インコーポレーテツド 薬物送達デバイス
CN102628869B (zh) * 2012-04-19 2014-04-02 上海蓝怡科技有限公司 提高甲胎蛋白抗体冻干稳定性的制剂
US9409662B2 (en) 2013-01-15 2016-08-09 Teva Pharmaceutical Industries, Ltd. Formulations of albu-BChE, preparation and uses thereof
WO2014147489A2 (en) 2013-03-15 2014-09-25 Teva Pharmaceutical Industries Ltd. Recombinant human albumin-human granulocyte colony stimulating factor for the prevention of neutropenia in pediatric patients
MA40904A (fr) * 2014-11-03 2017-09-12 Hygeia Tech Inc Compositions d'ester de phorbol et procédés pour traiter ou réduire la durée d'une cytopénie
RU2736045C2 (ru) 2015-03-06 2020-11-11 Бейондспринг Фармасьютикалс, Инк. Способ лечения рака, ассоциированного с мутацией ras
BE1023343B1 (nl) * 2015-05-20 2017-02-09 Mycartis Nv Opslagbuffer
CA2991059C (en) 2015-07-13 2024-01-16 Beyondspring Pharmaceuticals, Inc. Plinabulin monohydrate polymorphs
ES2852002T3 (es) * 2015-07-30 2021-09-10 Endor Tech S L Factor estimulante de colonias para su uso en el tratamiento del cáncer de páncreas o de colon
SG11201806583XA (en) 2016-02-08 2018-09-27 Beyondspring Pharmaceuticals Inc Compositions containing tucaresol or its analogs
US11229642B2 (en) 2016-06-06 2022-01-25 Beyondspring Pharmaceuticals, Inc. Composition and method for reducing neutropenia
CN106222221A (zh) * 2016-08-05 2016-12-14 山东科兴生物制品有限公司 制备重组人粒细胞刺激因子原液的纯化方法
WO2018096534A1 (en) 2016-11-22 2018-05-31 Sorrel Medical Ltd. Apparatus for delivering a therapeutic substance
JP2020503363A (ja) 2017-01-06 2020-01-30 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド チューブリン結合化合物およびその治療的使用
MY201811A (en) 2017-02-01 2024-03-19 Beyondspring Pharmaceuticals Inc Method of reducing neutropenia
WO2018187786A1 (en) * 2017-04-07 2018-10-11 La Jolla Institute For Allergy And Immunology Unipotent neutrophil progenitor cells, methods of preparation, and uses thereof
CN109420159A (zh) * 2017-08-23 2019-03-05 江苏泰康生物医药有限公司 一种重组蛋白药物的新型稳定制剂
AU2019212118A1 (en) 2018-01-24 2020-09-03 Beyondspring Pharmaceuticals, Inc. Composition and method for reducing thrombocytopenia via the administration of plinabulin
CN112105363A (zh) * 2018-02-01 2020-12-18 大连万春布林医药有限公司 用于通过施用普那布林和g-csf剂来减少化学疗法诱导的嗜中性白血球减少症的组合物和方法
US11583633B2 (en) 2018-04-03 2023-02-21 Amgen Inc. Systems and methods for delayed drug delivery
EP3632487B1 (en) 2018-10-05 2024-06-12 LTS Device Technologies Ltd Triggering sequence
CN111383745A (zh) * 2018-12-29 2020-07-07 医渡云（北京）技术有限公司 计算机数据处理方法、装置、存储介质及设备
US11267858B2 (en) 2019-05-31 2022-03-08 Spectrum Pharmaceuticals, Inc. Methods of treatment using G-CSF protein complex
US11684655B2 (en) * 2019-05-31 2023-06-27 Spectrum Pharmaceuticals, Inc. Methods of treating neutorpenia using G-CSF protein complex
CN112316120A (zh) * 2019-08-05 2021-02-05 天津派格生物技术有限公司 使用低动员型g-csf有效且安全治疗粒细胞减少症的方法
WO2021112654A1 (en) * 2019-12-05 2021-06-10 Hanmi Pharm. Co., Ltd. Methods of treating chemotherapy or radiotherapy induced neutropenia
KR102485892B1 (ko) * 2020-04-09 2023-01-09 주식회사 에이프릴바이오 고양이 과립구 집락 자극인자 및 혈청 알부민에 대한 항원 결합 단편을 포함하는 융합 단백질 및 이의 용도
CN111751552B (zh) * 2020-06-18 2022-09-16 广州市伊川生物科技有限公司 一种缺血修饰白蛋白测定试剂盒及其使用方法
KR102375269B1 (ko) * 2021-01-27 2022-03-17 한미약품 주식회사 단백질 액상 제제 및 이의 제조방법
JP2024513505A (ja) 2021-04-09 2024-03-25 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド 腫瘍を治療するための組成物及び方法
US11723955B1 (en) * 2022-05-13 2023-08-15 Allgenesis Biotherapeutics Inc. VEGFR fusion protein pharmaceutical composition

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2052712T3 (es) 1987-04-09 1994-07-16 Delta Biotechnology Ltd Vector de levadura.
JPH01215289A (ja) 1988-02-22 1989-08-29 Toa Nenryo Kogyo Kk 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法
FR2649991B2 (fr) 1988-08-05 1994-03-04 Rhone Poulenc Sante Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
FR2686900B1 (fr) 1992-01-31 1995-07-21 Rhone Poulenc Rorer Sa Nouveaux polypeptides ayant une activite de stimulation des colonies de granulocytes, leur preparation et compositions pharmaceutiques les contenant.
DE4242863A1 (de) * 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Stabile lyophilisierte pharmazeutische Zubereitungen von G-CSF
DE19549232C2 (de) * 1995-12-20 1998-05-20 Boehringer Mannheim Gmbh Verwendung von G-CSF in Kombination mit einem Chemotherapeutikum bei der Behandlung von Erkrankungen, die eine periphere Stammzelltransplantation erfordern
US7321023B2 (en) * 1997-11-07 2008-01-22 Incyte Corporation SP16 protein
JP3895109B2 (ja) * 1998-03-06 2007-03-22 中外製薬株式会社 蛋白非添加製剤
US6831158B2 (en) * 2000-01-10 2004-12-14 Maxygen Holdings Ltd. G-CSF conjugates
US6555660B2 (en) * 2000-01-10 2003-04-29 Maxygen Holdings Ltd. G-CSF conjugates
EP1276856A4 (en) 2000-04-12 2004-06-09 Human Genome Sciences Inc ALBUMIN FUSION PROTEINS
AU2002302814A1 (en) * 2001-06-08 2002-12-23 Powderject Vaccines, Inc. Spray freeze-dried compositions
WO2005003296A2 (en) 2003-01-22 2005-01-13 Human Genome Sciences, Inc. Albumin fusion proteins
JP5424521B2 (ja) 2001-12-21 2014-02-26 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド アルブミン融合タンパク質
US20080108560A1 (en) 2002-03-05 2008-05-08 Eli Lilly And Company Heterologous G-Csf Fusion Proteins
CN1241946C (zh) * 2002-07-01 2006-02-15 美国福源集团 对多种细胞具刺激增生作用的人血清白蛋白重组融合蛋白
US20070041987A1 (en) * 2003-03-19 2007-02-22 Daniel Carter Fragments or polymers of albumin with tunable vascular residence time for use in therapeutic delivery and vaccine development
US6972332B1 (en) * 2004-05-20 2005-12-06 Acura Pharmaceuticals, Inc. Process for the production of opiates
MX2008001865A (es) * 2005-08-12 2008-04-15 Human Genome Sciences Inc Proteinas de fusion de albumina.
CA2584927C (en) * 2006-04-13 2011-02-08 Wix Filtration Corp. A body for actuating a standpipe of a replaceable filter element
JP2008146587A (ja) * 2006-12-13 2008-06-26 Sony Corp 表示装置、表示プログラム、表示方法、画像提供装置、画像提供プログラム、画像提供方法及び記録媒体
EP2387420A2 (en) 2009-01-16 2011-11-23 Teva Pharmaceutical Industries Limited New stable formulations of recombinant human albumin-human granulocyte colony stimulating factor fusion protein

Also Published As

Publication number Publication date
CA2749802A1 (en) 2010-07-22
EP2387420A2 (en) 2011-11-23
SG196821A1 (en) 2014-02-13
US20130129669A1 (en) 2013-05-23
IL214052A0 (en) 2011-08-31
EA201190080A1 (ru) 2014-03-31
JP2012515221A (ja) 2012-07-05
IL214051A0 (en) 2011-08-31
US20100297062A1 (en) 2010-11-25
KR20110132326A (ko) 2011-12-07
ZA201105171B (en) 2015-12-23
WO2010083439A3 (en) 2010-09-10
US8323634B2 (en) 2012-12-04
AU2010204552B2 (en) 2014-05-01
US8993519B2 (en) 2015-03-31
US20100227818A1 (en) 2010-09-09
UA105201C2 (uk) 2014-04-25
WO2010083434A3 (en) 2010-09-10
SG172941A1 (en) 2011-08-29
CN102395379A (zh) 2012-03-28
US20150202268A1 (en) 2015-07-23
CN102395379B (zh) 2015-07-22
CA2749802C (en) 2016-08-23
NZ594056A (en) 2013-03-28
AU2010204552A1 (en) 2011-08-04
MX2011007583A (es) 2011-12-14
MX2011007582A (es) 2011-12-14
CN102378635A (zh) 2012-03-14
AU2010204547A1 (en) 2011-07-28
SG172940A1 (en) 2011-08-29
AU2010204547B2 (en) 2014-01-23
EP2387419A2 (en) 2011-11-23
JP5753095B2 (ja) 2015-07-22
KR20110132327A (ko) 2011-12-07
BRPI1005159A2 (pt) 2018-04-03
BRPI1004940A2 (pt) 2018-06-19
WO2010083439A2 (en) 2010-07-22
EA201190079A1 (ru) 2013-02-28
UA103221C2 (uk) 2013-09-25
CA2749786A1 (en) 2010-07-22
JP2012515222A (ja) 2012-07-05
EA023344B1 (ru) 2016-05-31
WO2010083434A2 (en) 2010-07-22

Similar Documents

Publication Publication Date Title
NZ594055A (en) New stable formulations of recombinant human albumin-human granulocyte colony stimulating factor fusion protein
NZ608502A (en) Polypeptides that bind to human complement component c5
EP2727583A3 (en) Drug carrier and drug carrier kit for inhibiting fibrosis
AR117403A2 (es) Formulaciones de anticuerpos
TR200502189T1 (tr) Kompozisyonlar ve farmakolojik etken maddelerin aktarımı için yöntemler.
UA115648C2 (uk) Доставка терапевтичних агентів до цнс
MX2007007458A (es) Derivados de quinazolina para inhibir crecimiento de celulas cancerigenas y metodo para la preparacion de los mismos.
EP2390265A3 (en) Insulinotropic peptide derivative wherein its N-terminal amino acid is modified
UA96449C2 (en) Stable laquinimod preparations
NZ603813A (en) Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of histidyl-trna synthetases
MY151184A (en) A polypeptide complex comprising non-peptidyl polymer having three functional ends
EP2626427A3 (en) Sirna conjugate and preparation method thereof
MY169461A (en) Pharmaceutical composition
NZ603161A (en) Superior efficacy of cd37 antibodies in cll blood samples
PH12012501895A1 (en) Long-acting formulations of insulins
UA105078C2 (uk) Фармацевтична композиція, яка містить тетрагідрофолієву кислоту
MX346879B (es) Formulaciones de ketorolaco listas para su uso.
GEP20125684B (en) Dipeptidyl peptidase inhibitors weekly administration
UA102236C2 (uk) Похідні еритропоетин-міметичного пептиду та їх фармацевтичні солі, їх одержання і застосування
NZ601592A (en) Recombinant elastase proteins and methods of manufacturing and use thereof
WO2004112838A3 (en) Codrugs of diclofenac
EP1845083A3 (en) New arylsulfonohydrazide inhibitors of enzymes MurC and MurD
UA109544C2 (uk) Фармацевтична композиція, що містить парацетамол, та спосіб її виготовлення
SG162766A1 (en) Benzooxazole-2-on derivatives as lipase and phospholipase inhibitors
UA93365C2 (ru) Инъекционная форма диклофенака и его фармацевтически приемлемых солей (варианты) и способ его приготовления (варианты)

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 15 JAN 2017 BY DENNEMEYER SA

Effective date: 20131218

LAPS Patent lapsed